Monument Health Cancer Care Institute

Rapid City, South Dakota 57701

2 studies enrolling now · 4 studies all time

What they study most

Extensive-stage Small-cell Lung Cancer, Gastrointestinal Cancer, Immune Checkpoint Inhibitors, Melanoma, Metastatic Pancreas Adenocarcinoma, Metastatic Solid Tumor, Nonsmall Cell Lung Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenosquamous Carcinoma

Studies at this site

• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) — Recruiting now
• Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma — Available (expanded access)
• To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) — Completed
• Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population — Running, not enrolling